An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Trial Profile

An Open-Label Extension Study to Evaluate the Safety of Etanercept in Pediatric Subjects With Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; Registrational
  • Sponsors Amgen
  • Most Recent Events

    • 06 Nov 2017 Results published in the Journal of Clinical Pharmacology.
    • 07 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2017 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top